Desert Hot Springs Project

The MEMO Desert Hot Springs Project

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

Confidential Information
This presentation is confidential. The contents are not to be reproduced or distributed to the public or press. The information contained herein, while obtained from
sources which are believed to be reliable, is not guaranteed as to its accuracy or completeness. The information contained herein may be amended. The information
contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of evaluating the subject matter of this presentation. No persons
are authorized to give any information or make any representation in respect of the subject matter of this presentation and any such information or representation must
not be relied upon.
By accepting a copy of this presentation, the recipient agrees that neither it nor any of its representatives or agents shall use this presentation or the information
contained herein for any purpose other than for making an informed decision regarding the subject matter of this presentation and shall not divulge it to any other party
and shall return all copies of the presentation promptly upon request.

Forward Looking Information

This presentation contains forward-looking information relating to our business strategy and measures to implement strategy, rental income, occupancy rates,
expenditures (including the amount and nature thereof), fees, cash flow, investment payouts, valuations, refinancings and other matters. These statements relate to future
events or future performance. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "budget", "plan", "estimate",
"expect", "forecast", "may", "project", "potential", "target", "intend", "could", "might", "should", "believe" and similar expressions. Forward-looking statements are based
on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could
cause actual events or results to differ materially from those anticipated in the forward-looking statements. Some of the risks and other factors that could cause results to
differ materially from those expressed in the forward-looking statements include, but are not limited to: general economic conditions in the United States and globally;
governmental regulation of our industry; unanticipated operating events; the availability of capital on acceptable terms; exchange rates, interest rates the need to obtain
required approvals from regulatory authorities; liabilities inherent in our operations; and changes in tax laws. Readers are cautioned that this list of risk factors should not
be construed as exhaustive.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be
correct. We cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the
same, in whole or in part, as those set out in the forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this
cautionary statement. We undertake no obligation to update or revise publicly any forward-looking statements except as required by applicable legislation. The forward-
looking statements made herein relate only to events or information as of the date on which the statements are made. The reader is cautioned not to place undue
reliance on forward-looking statements.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

Financial Projections
This presentation contains certain financial projections. These financial projections relate to future performance and reflect our views as at the date of this presentation
and are subject to known and unknown risks, uncertainties and assumptions that may cause future results, performance or achievements to differ materially from those
expected. We believe the expectations reflected in these financial projections are reasonable but no assurance can be given that these expectations will prove to be
correct and these financial projections should not be unduly relied upon. We cannot guarantee future results, level of activity, performance or achievements.
Consequently, we make no representation that the actual results achieved will be the same in whole or in part as those set out in the financial projections.

The financial projections were prepared by management to assist with planning and operational decision making. The financial projections have been included in this
presentation as a tool to make an informed decision regarding the subject matter of this presentation and readers are cautioned that the financial projections may not be
appropriate for other purposes. We have approved of these financial projections as of the date of this presentation.

The financial projections contained in this presentation are expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance upon any
such financial projections, which speak only as of the date made. Except as required by applicable law, we do not undertake or accept any obligation or undertaking to
release publicly any updates or revisions to any financial projections to reflect any change in our expectations or any change in events, conditions, assumptions or
circumstances on which any such financial projections are based. In addition to the foregoing, your investment pursuant to the terms of this document is subject to the
following risk factors. The occurrence of any of the following risks, among others, could materially and adversely affect our business, financial condition, and operating
results, which may result in a loss of your investment.

We have a limited operating history and a small management team and sta. Our proposed operations are subject to all of the risks inherent in a growing
business enterprise, including continuing operating losses. The likelihood of our success must be considered in light of the problems, expenses, difficulties,
complications, and delays frequently encountered in connection with the growth of an early stage business, products, and channels of distribution, and current and future
development, as well as in the competitive nature of the medical marijuana industry. If these risks materialize, our business could be seriously harmed. We cannot
guarantee we will be profitable, have a positive cash flow, or be able to continue in business.

Our business is speculative and involves substantial risks. Factors bearing upon the success of our business will include, among others, the quality of our
product, the attractiveness of the packaging, the adequacy of distribution in the market place, and the experience and skill of our management. In addition, more
general economic conditions will also affect our potential profitability.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

We face substantial competition from several competitors, some of whom have far greater resources, which may make it more dicult for us to achieve
significant market penetration. The market for quality medical marijuana products is intensely competitive, subject to rapid change, and significantly affected by new
product introductions and other market activities of industry participants. While we believe that our products occupy a unique niche in each individual marketplace, other
companies offer similar products that compete for the same demographic, and could compete more directly with us by developing products functionally the same as
ours. Most of these competitors are larger and better funded companies with significantly greater resources for product development and marketing. In addition to the
current market players, at any time, other companies may develop additional competitive products in the same category. If we were unable to compete effectively
against existing or future competitors, net revenues of our products would decline. Some of our competitors may compete by lowering the price of their products or
ancillary supplies. If these competitors products were to gain acceptance by the consumers, a downward pressure on prices for our products could result. If prices
were to fall, we may not grow sufficiently to achieve profitability.

We may be unable to gain any significant market acceptance for our products or establish a significant market presence with the retailers and
consumers. If we are unable to continue to gain market acceptance, we will not be able to continue to generate revenue and our business will fail. Our
growth strategy is substantially dependent upon our ability to market our current and future products successfully to retailers who sell our products. However, it may be
very difficult to achieve significant acceptance and product appeal, due to competition and other factors outside of our control. Such acceptance, if achieved, may not
be sustained for any significant period of time nor build to an acceptable volume that is sufficient to maintain our business. In addition, there is no guarantee that any
acceptance by customers will continue. Failure of our products to achieve or sustain market acceptance could have a materially adverse effect on our business, financial
conditions, and the results of our operations.

Establishing and maintaining a customer base is dicult to achieve and increase, especially since consumers are always cost conscious. If we cannot
continue to attract and expand our customer base, we face a high risk of business failure, which would result in the loss of your investment. Attracting,
building, and managing a retail customer base through the efforts of our Management and employees is very difficult to accomplish in the medical marijuana market.
Customers are very cost sensitive and will switch to any other product based on cost or taste. If we cannot continue to build a consistent customer base, our future
sales and operating results will be negatively impacted and our business could fail.

We use third parties to produce some of the products for our brands. We utilize third parties to grow medical marijuana for our products and also to manufacture
some of our medical marijuana products. We need to work with farmers to grow medical marijuana for us in the types and styles we are marketing. We may have
disagreements with our farmers due to costs, production runs, timing, and availability. Any unresolved issues may lead to the loss of these established relationships
endangering our business.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

Our business could also suffer as a result of a manufacturers inability to produce goods on time and to certain specifications. Our products are manufactured to our
specifications and under our own brand. The inability of a manufacturer to complete orders of products in a timely manner or to meet quality standards could cause us to
miss the delivery date requirements of our customers for those items. Although we have developed plans for such incidents, this could result in the cancellation of orders,
refusal to accept deliveries or a reduction in purchase prices, any of which could have a materially adverse effect on our financial condition and results of operations.

We are dependent on relationships with key merchandise supply partners, distributors, and retail chains, and the ability to create more such relationships.
Our business model for all of our products offered is retail and supply-centric. Successful implementation of it is predicated on our ability to create and nurture strong
partnerships with medical marijuana dispensaries. If we are unable to maintain existing partnerships or establish new ones, our revenues may decrease and we may never
attain profitability.

Unfavorable Publicity or Consumer Perception. The medical marijuana industry is highly dependent upon consumer perception regarding the safety, efficacy, and
quality of the medical marijuana produced. Consumer perception of medical marijuana products can be significantly influenced by scientific research or findings, regulatory
investigations, litigation, media attention, and other publicity regarding the consumption of medical marijuana products. There can be no assurance that future scientific
research, findings, regulatory proceedings, litigation, media attention, or other research findings or publicity will be favorable to the medical marijuana market or any
particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention, or other publicity that are
perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for medical marijuana
products and the business, results of operations, financial condition and cash flows of our business. Our dependence upon consumer perceptions means that adverse
scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material
adverse effect on our business, the demand for our products, and the our results of operations, financial condition, and cash flows. Further, adverse publicity reports or
other media attention regarding the safety, efficacy and quality of medical marijuana in general, or our products specifically, or associating the consumption of medical
marijuana with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise
even if the adverse effects associated with such products resulted from consumers failure to consume such products appropriately or as directed.

Our insurance coverage may be inadequate to cover all significant risk exposures. We will be exposed to liabilities that are unique to the products we provide.
While we intend to maintain insurance for certain risks, the amount of our insurance coverage may not be adequate to cover all claims or liabilities, and we may be forced
to bear substantial costs resulting from risks and uncertainties of our business. It is also not possible to obtain insurance to protect against all operational risks and
liabilities. The failure to obtain adequate insurance coverage on terms favorable to us, or at all, could have a material adverse effect on our business, financial condition and
results of operations. We do not have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and diversion of
resources.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

We are subject to regulations of and licensing by various governmental agencies. The medical marijuana industry is subject to extensive regulation by the
California Department of Public Health and local authorities. These regulations and laws dictate such matters as how medical marijuana businesses can be organized,
who is allowed to buy medical marijuana products, and how we are to acquire the raw materials that go into the manufacturing of retail products. In addition, new
regulations or requirements or increases in excise taxes, income taxes, property and sales taxes or international tariffs, could negatively impact us financially. Future legal
challenges to the industry, either individually or in the aggregate, could harm our business if they impose requirements that we are unable to meet.

We have all of the requisite licenses and permits to operate at our present level, however, future growth may require additional licenses or permits. The inability or failure to
attain any such required items could result in our inability to expand our business as described in this document.

Changes in federal practices with respect to the use of medical marijuana could adversely impact us. A number of states have enacted laws allowing their
citizens to use medical marijuana. However, the state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on
a national level. The Obama administration has effectively stated that it is an inefficient use of resources to direct federal law enforcement agencies to prosecute those
lawfully abiding by state-designed laws allowing the use and distribution of medical marijuana.

There is no guarantee that the administration will not change its policy regarding the low-priority enforcement of these federal laws. Additionally, any future administration
could decide to aggressively enforce these federal laws. Any change in the federal governments enforcement of current federal laws could adversely affect our business,
operations, our customers, or the sales of our products.

Rising fuel and freight costs may have an adverse impact on our sales and earnings. The recent volatility in the global oil markets has resulted in rising fuel and
freight prices, which many shipping companies are passing on to their customers. Our shipping costs, and particularly our fuel expenses, have been increasing and we
expect these costs may continue to increase. Due to the price sensitivity of our products, we do not anticipate that we will be able to pass all of these increased costs on
to our customers. The increase in fuel and freight costs could have a material adverse impact on our financial condition.

Infringement of our brand name may damage our business. Our products are branded consumer products. Our ability to distinguish our brand name from those of
our competitors depends, in part, on the strength and vigilant enforcement of our brand name. Competitors may use trademarks, trade-names or brand names that are
similar to ours, thereby weakening our intellectual property rights. If our competitors infringe on our rights, we may have to litigate in order to protect such rights. Litigation
may result in significant expense and divert our attention from business operations. In addition, we cannot assure you that we would be successful in protecting our rights.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

We may not be able to raise adequate capital. If we are unable to successfully obtain the loan contemplated by this document, we will be unable to purchase the
property referred to herein. This will necessitate revision of our business plan and may require that us to seek additional capital on less favorable terms. Our inability to
obtain required capital could preclude us from achieving profitability.

We are dependent on key management. We are highly reliant on the services of our founders, Ata and Odila Gonzalez, and their actions greatly influence our success.
We are also highly dependent on the other members of our management team and the outlined projections in this document rely on that team remaining with us. The
implementation of our business plan and our continued success relies on key members of the management team and sales, marketing, and finance personnel. These
employees may not continue to work for us and we may not be able to replace these employees with personnel of similar caliber, should they leave us. Should one or
more of these employees leave us, our financial results may be impaired.

We may have diculty managing our growth. Our ability to compete effectively and to manage future growth will depend on our ability to continue to implement and
improve operational, financial, and management information systems on a timely basis and to expand, train, motivate, and manage our work force. We intend to rapidly
and significantly expand our operations, and anticipate that further significant expansion will be required to implement our business strategy and penetrate market
opportunities. This expansion is expected to place a significant strain on our managerial, operational, and financial resources. To manage the expected growth of our
operations, we will be required to develop and maintain operational and financial systems and procedures and controls. There can be no assurance that our personnel,
systems, procedures, and controls will be adequate to support our operations, and any deficiencies in that regard could have a material adverse effect on our business,
financial condition, or results of operations.

Our growth will depend on our ability to develop awareness. We believe that establishing widespread awareness will be critical to achieving widespread acceptance
and adoption of our products. Promoting and positioning of our products will depend largely on the success of our marketing efforts, distribution channels, and our ability
to provide high quality service. Establishing a significant presence for medical marijuana products often requires substantial marketing investment to generate the
necessary adoption rates. Promotional activities may not yield increased revenues, and even if they do, any increased revenues may not offset the expenses we incur in
building our essence and our products.

There is no marketability or liquidity of our shares. The nature of early stage investing dictates a long period between the initial investment and realization of gains, if
any. Such investments, if successful, typically take a number of years from the date of investment to reach a state of maturity where distributions or liquidation are
possible. Moreover, an investment in us will be subject to restrictions on transfer because these are unregistered securities. There is no established public market for any
of our securities, nor is any such market likely to develop in the foreseeable future. None of our securities have been registered under the Securities Act of 1933 (Act), nor
qualified under applicable state or other security laws, and we have no present plans to register any of our securities for public sale. None of our securities may be resold
or otherwise transferred unless they have been registered under the Act and qualified under applicable state or other security law, or unless they are exempt from such
registration. This is a long-term investment.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

The shares cannot be transferred. The shares (Shares) into which the loan amount may be converted pursuant to this document will be restricted securities, which
have not been registered under federal or state securities laws and will not be transferable. This offering is made pursuant to exemptions from the registration requirements
of federal securities laws. In addition, the offering will not be registered in any state in reliance on exemptions from registration for private offerings under state securities
laws. To satisfy the requirements of certain exemptions from registration, each investor must acquire his or her Shares for investment purposes only and not with a view
towards distribution. Consequently, certain conditions of the Act may need to be satisfied prior to any sale, transfer, or other disposition of the Shares. Some of these
conditions may include a minimum holding period, availability of certain reports, including financial statements from us, limitations on the percentage of Shares sold and the
manner in which they are sold. We will serve as our own transfer agent and registrar and can prohibit any sale, transfer or disposition unless we receive an opinion of
counsel provided at the holders expense, in a form satisfactory to us, stating that the proposed sale, transfer or other disposition will not result in a violation of applicable
federal or state securities laws and regulations.

The Shares will bear the following legend: THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 NOR REGISTERED NOR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR
HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF
COUNSEL SATISFACTORY TO THE BORROWER, SUCH QUALIFICATION AND REGISTRATION IS NOT REQUIRED.

Investors in this offering will not have the opportunity to have us redeem their Shares. Accordingly, purchasers of the Shares must be willing and able to bear the economic
risk of their investment for an indefinite period of time. Investors will not be able to liquidate their investment in the event of an emergency.

The Shares are subordinated to our debt obligations. The Shares are subordinate to the rights of all of our creditors. We may borrow additional funds in the future as
necessary to implement our business plan. Thus, in the event of our liquidation, holders of Shares would receive no value until all creditors claims are fully satisfied.

We may not have sucient cash to pay any distributions on the Shares. We have never paid dividends or distributions on our common stock. Further, we
anticipate that we will not do so in the future as our cash will be needed for business development.

The oering price of our Shares and our companys valuation is arbitrary. The offering price of the Shares and our companys valuation was determined arbitrarily
by us and bears no relationship to earnings, asset values, book value, or any other recognized criteria of value.

We depend on the reliability and continuity of our data management systems. As a retail centric operation, we are dependent upon the continued reliability of our
data management and inventory tracking systems. Although we have reliable systems in place, there is no guarantee that these systems will continue to be accurate and
consistent in the future.

www.GFarmaLabs.com
 Disclaimers Desert Hot Springs Project

Risks associated with intellectual property. Our inability to adequately protect our intellectual property could allow our competitors and others to provide marijuana
products with formulas and other intellectual property rights similar to our own, which could substantially impair our ability to compete. Despite our efforts to safeguard our
unpatented and unregistered intellectual property rights, we may not be successful in doing so or the steps taken by us in this regard may not be adequate to detect or
deter misappropriation of our formulas or to prevent an unauthorized third party from copying or otherwise obtaining and using our products and other proprietary
information. Our inability to adequately protect our intellectual property could allow our competitors and other to produce similar products and could substantially impair
our ability to compete.

Management may invest or spend the proceeds of this oering in ways with which you may not agree and ways in which may not yield favorable return.
Our Management will exert control over the proceeds from this offering. Our shareholders may not find these uses desirable and our use of proceeds may not yield a
significant return or any return at all. Because of the number and variability of factors that determine the use of the net proceeds of this offering, we cannot provide
assurance that these uses will not vary substantially from our current planned uses.

www.GFarmaLabs.com
 Desert Hot Springs Project

Executive Summary
G FarmaLabs Limited (G FarmaLabs") is headquartered in Corona, California and is a Nevada Corporation.

G FarmaLabs CA. offers a selection of premium extracts, chocolates, confections, fine cultural accessories, and
other emerging byproducts to help with the everyday lifestyle. However, G FarmaLabs Limited does not directly
grow, process, own, handle, transport, or sell cannabis or related products.

G FarmaLabs management has over 30 years of combined successful experience in the legal cannabis industry in
California.

G FarmaLabs Limited strategy is to scale with the 2.5 acre property in Desert Hot Springs. The project consists of
erecting a 56,000sf greenhouse and 6,000sf of headhouse for the production, processing and storing of cannabis.
The Desert Hot Springs Project will make the G FarmaLabs, the first licensed cannabis brand of products in the
State of California.

www.GFarmaLabs.com
 Desert Hot Springs Project

What We Do
Financing solutions. Our Financing Solutions include leasing state guideline approved growing spaces and related
facilities (commercial real estate, agricultural properties, and equipment) to licensed marijuana business operators for
their production needs. G FarmaLabs Limited consultants customize the build out with the state licensed operators. In
this manner, we are able to assist clients increase memberships to their collectives, design and finance cultivation and
production facilities, and forge relationships.

Seed to sale services. Our turnkey, seed-to-sale service solutions offer service and tools to maintain compliance from
point of corporate registration, through to establishing procedures, processing, tracking and reporting product. We have
the expertise to keep our clients in compliance with the ever changing local, state, and federal laws.

Our G FarmaLabs Limited Intellectual Property, Packaging, Branding and Manuals is what sets us apart from the rest. Our
consultants will hold your hand every step of the way to successfully establish the G FarmaLabs Brands.

www.GFarmaLabs.com
 Desert Hot Springs Project

Why Invest in G FarmaLabs Limited?

G FarmaLabs Limited currently has one (1) 2.5 acre parcel under contract in Desert Hot Springs, first city in CA.
to license cannabis cultivation.

The capital raised will allow the Company to execute 56,000sf of canopy for cannabis cultivation and 6,000sf of
headhouse for the processing and storing of harvested marijuana flowers. This raise will provide the initial
financing to purchase the land.

G FarmaLabs Limited CEO successfully initiated the build-out of the first cultivation facility for the CA. Collective
in July 2010, which showed profitability within a ninety-day operating window.

Managements strategic business plan is to scale its service model by expanding its CA. cultivation operations
and becoming a licensed brand in the state.

We are targeting a fully-compliant and licensed cultivation facility, and plan to scale the Companys financing and
service-based business model throughout California.

Investors coming into the raise at this early stage will be the ones who capitalize the greatest. We plan on
growing our valuation at least ten times what it is worth today, from 20 million to 200 million within 24 months.

www.GFarmaLabs.com
 Desert Hot Springs Project

Estimated Loan Amount

We are seeking $415,000 loan for 2 years at interest rate of 10% with stock option provided to the creditor at a valuation
of 20 million USD.
Description Cost Loan Repayment Schedule
Land Purchase (2.5 Acres) $ 330,000 G FarmaLabs will repay the loan amount by the following repayment schedule: (see exhibit A)
Conditional Use Permit Fees $ 75,000
Year 1 - 10% Interest Only payments ($41,500)
Miscellaneous fees $ 10,000
Year 2 - 10% Interest Only payments ($41,500)
Total $ 415,000

At the end of two years the creditor will have the option to receive cash payment for the total amount or
purchase convertible common stock of the company at 2015 valuation of $20 M. [* see exhibit B]

Products and Deliverables

The G FarmaLabs Desert Hot Springs Production and Processing Facility is intended to produce cannabis
flowers and byproducts for extracts. The facility is expected to distribute the cannabis through G
FarmaLabs in-house distribution routes throughout the state of California to 1,000's of retail outlets. It is
estimated that 75% of the flower production will be utilized for infusion of G FarmaLabs products and
25% will be sold as flower to retail outlets within our distribution system.

www.GFarmaLabs.com
 Desert Hot Springs Project

Annual production estimation

Total Plants 2,400 unit
Product per plant 5 lbs
No of harvests per year 3
Total Production 36,000 lbs
Trim 15%
Byproduct 5,400 lbs

End of Year 1
Projected Annual Income
1st Scenario 2nd Scenario 3rd Scenario
G FarmaLabs is expecting to use 75% of the flower Flower price/lb 1000 2000 3000
Trim price/lb 50 100 150
production in house. The table below shows our projected
Gross revenue 31,635,000 63,270,000 94,905,000
revenue and profit stream using different expected price per
Expenses 10,218,105 20,436,210 30,654,315
pound of flower. The detailed calculations are shown below. Total Profit 21,416,895 42,833,790 64,250,685

Required Rate of return 10% NPV Calculation

Development Cost $5,500,000 The NPV of the project is calculated by using 10 years project life and 10% required rate of return.
Project Duration 10 years The table below shows the sensitivity analysis of NPV with the variation of net profit margin and production over the years.
NPV* $235,223,852

NPV Total Production (lbs)

$235,223,852 30,000 33,000 36,000 39,000 $42,000 45,000
40% 113,245,370 125,076,454 136,907,539 148,738,624 160,569,708 172,400,793

Margin 50% 142,823,081 157,611,937 172,400,793 187,189,649 201,978,505 216,767,360

60% 172,400,793 190,147,420 207,894,047 225,640,674 243,387,301 261,133,928

68% 195,175,631 215,199,742 235,223,852 255,247,963 275,272,074 295,296,185

70% 201,978,505 222,682,903 243,387,301 264,091,699 284,796,097 305,500,495

75% 216,767,360 238,950,644 261,133,928 283,317,212 305,500,495 327,683,779

www.GFarmaLabs.com
 Desert Hot Springs Project

Capital Expenditure Summary

After the land acquisition, G FarmaLabs expects to begin on the construction of the greenhouse and the equipment purchase which they have potential funding in place.
Capital Expenditure Cost
Greenhouse build out $4,500,000

Equipment and supplies $500,000

Miscellaneous cost $500,000

Total CapEx $5,500,000

Physical Structure and Location

Location: North side of San Jacinto
lane, east of Little Morongo road, City
of Desert Springs
Head House: 6,840 SF
Green House: 53,362 SF
Total: 60,202 SF

Figure: Conceptual Development plan Figure: Google satellite view of the location

www.GFarmaLabs.com
Attractive Market Opportunity Desert Hot Springs Project

www.GFarmaLabs.com
Organizational Structure Desert Hot Springs Project

Ata Gonzalez CEO

Odila Gonzalez Secretary

Nicole Gonzalez COO

Humberto Torres Fay Farouk Luigi De Dominicis

Chief Production Officer Chief Strategy Officer Chief Technology Officer

Dr. Cristina Gonzalez

Collective Director CA. Territory

www.GFarmaLabs.com
 Management Desert Hot Springs Project

We are led by a passionate Management team of experienced professionals which gives us extensive leadership experience across all core functional areas of
the business. The names, titles, and background of our Management as of the date of this Memorandum are as follows:

Name Title
Ata Gonzalez Chief Executive Officer, Founder and Director
Odila Gonzalez Co-Founder, Secretary, and Director
Nicole Gonzalez Chief Operating Officer and Director
Humberto Torres Chief Production Officer
Fay Farouk Chief Strategy Officer
LuigiDe Dominicis Chief Technology Officer
Dr. Cristina Gonzalez California Territory Collective Director

Ata Gonzalez - Chief Executive Officer and Director GFarmaLabs Limited

Ata Gonzalez is G FarmaLabs founder and Chief Executive Officer who leads the brands vision, global expansion, and marketing. Mr. Gonzalez has spent
nearly 20 years as an entrepreneur. Under his leadership, G FarmaLabs became Americas first national cannabis products brand. Mr. Gonzalez is also an
author and public speaker. In 2009, Mr. Gonzalez attended Oaksterdam University. After learning about all phases of the marijuana industry, he went to work at
a California collective to get real hands-on experience. Soon after, he began building and overseeing a team of professional managers to maximize
productivity and efficiency in cannabis production and dispensary operations. Seeing firsthand the growing demand for cannabis edibles and extracts, Mr.
Gonzalez founded the G FarmaLabs brand and marketed its products to set the standard for quality, consistency, and packaging appeal. For the last five
years, Mr. Gonzalez has driven a strong track record of results, execution excellence and improved efficiency while also driving the brand forward in an ever-
changing regulatory landscape. Under his leadership and direction their delicious chocolates/confections and extract products have won awards and high
praise throughout the growing national/global cannabis community.

Nicole Gonzalez - Chief Operating Officer and Director GFarmaLabs Limited

Nicole Gonzalez is G FarmaLabs Chief Operating Officer and is responsible for overseeing the day-to-day leadership and general management of the brand
and its IP. In this role, Mrs. Gonzalez has helped establish G FarmaLabs as a respected, award-winning national cannabis brand. Mrs. Gonzalezs
responsibilities and influence extend throughout all areas of the organization including strategic planning and execution, corporate management, product
development, technology deployment, and customer and network operations. Mrs. Gonzalez is a second generation Cuban-American and the member of a
fourth generation tobacco family. Her grandfather, a master cigar blender and highly regarded figure in the industry, Pedro Martin, founded Tropical Tobacco.
Mr. Martin launched his brand in 1978 after working in the Detroit area for DWG Cigar Group. Mrs. Gonzalez witnessed and experienced her grandfather
position his company to be acquired by Eduardo Fernandez in 2002 - known for his Nicaraguan-based Aganorsa farms and Casa Fernandez brand. Her
mother, Maria Martin, served as the president of Tropical Tobacco for 18 years prior to its sale and later became national sales manager for Camacho Cigars in
2003. Mrs. Martin was an integral part of the Camacho brands exit strategy, which took place from the time of her hiring to 2008 by Davidoff Cigars for an
undisclosed amount. Mrs. Gonzalez carries many lessons learned from the cigar industry into the future of the G FarmaLabs brand.

www.GFarmaLabs.com
 Management (Continued) Desert Hot Springs Project

Odila Gonzalez Co-Founder, Secretary, and Director GFarmaLabs Limited CA

Co-Founder of G FarmaLabs, Mrs. Gonzalez is a South Florida native who, together with her husband, owned and operated a successful small chain of
Cuban restaurants in Miami called Rincon Criollo. Mrs. Gonzalez was an integral part of the business, responsible for licensing and management of
these restaurants for over 25 years. Her knowledge and business acumen came into play when her son, Ata Gonzalez, asked for a small amount of
capital investment to help with a start-up. This initial funding would allow Mr. Gonzalez to G FarmaLabs. Her many years in business allow her to see
obstacles and advise the Company on how to overcome them. She continues to be the rock behind the G FarmaLabs brand of products.

Dr. Cristina Gonzalez California Territory Collective Director GFarmaLabs CA

Dr. Cristina Gonzalez will be the Director of the California Territory, Non Profit Collective of G FarmaLabs once she obtains the required licensing for the
cultivation facility in Desert Hot Springs. Dr. Gonzalez is a licensed pharmacist in the states of Florida & California. As Director, Dr. Gonzalez will be
responsible for overall management of the brand in California, its financial reporting, transparency, and for multiple corporate functions and long-range
planning. Dr. Gonzalez has been pharmacy manager at Walgreens Pharmacy and employed with that company for the last twenty-one years. Her
experience in that capacity led her interest into the cannabis industry. With a strong desire to lead the California Collective, Dr. Gonzalez plans to
develop the G FarmaLabs brand with a corporate approach, ensuring its financial disclosures and that its regulatory compliance remains timely,
transparent, and efficient. Dr. Gonzalez attended Florida Atlantic University in Boca Raton, Florida and later graduated with a Doctor of Pharmacy
degree from Nova Southeastern University in Davie, Florida.

Luigi De Dominicis Chief Technology Officer GFarmaLabs Limited

G FarmaLabs Chief Technology Officer, Luigi De Dominicis, leads the Operations and Professional Extractions Group (PEG) team. Mr. De Dominicis
brings to G FarmaLabs a diverse cross-industry background in leadership, infrastructure development, process improvement, project management,
operations management, and professional services. Luigi has held positions in both, financial organizations and small business organizations, upon
which he draws experience to create a best of both worlds approach to leadership, team building, efficiency, and protocols. Mr. De Dominicis brings
16 years of upper level management experience to G FarmaLabs. Beginning his career as a loan officer in the mortgage industry at 19 years old, Luigi
quickly climbed the corporate ladder. Recognized for his leadership skills, he became Vice President of sales for a multi-million dollar financial company
by age 22. In order to keep up with the booming loan demands, Mr. De Dominicis created an efficient protocol for mortgage loan processing. He
scouted and assembled teams, finding 31 their niche and putting them in the right places to handle specific tasks. Capitalizing on his success, Mr. De
Dominicis expanded into the insurance industry where he oversaw multiple agencies and handpicked agents and customer service representatives for
each location and together they increased the companys sales by 40% and retention rate by 25% in less than a year. Mr. De Dominicis clear vision
made him look to California where an emerging industry was being formed. In 2011, he decided to relocate his family and join the G FarmaLabs team.
For two years he was involved in cannabis production and curing methods for the G FarmaLabs California collective. As extracts became more popular,
Mr. De Dominicis became recognized for his leadership abilities and was promoted to handle all the Co2 extraction processes and refinement methods.
Today Mr. De Dominicis oversees the PEG team and their operational structure. Luigi shares the founders vision of creating innovative, consistent, and
high quality products that set the standard in the cannabis industry.

www.GFarmaLabs.com
 Team Member Biographies (Continued) Desert Hot Springs Project

Humberto Torres Chief Production Officer GFarmaLabs Limited

G FarmaLabs Chief Production Officer has more than 18 years experience in the area of business operations management and development.
Progressively responsible experience includes directing as many as 100 employees in companies with revenues in excess of $500 million. Mr. Torres has
led these companies through acquisition mergers, survival, turnaround, and growth mode.

From 1994 through 2000, Mr. Torres worked for several banking institutions quickly rising through the ranks, becoming one the youngest retail sales
managers for Great Western Bank at the age of 23. Mr. Torres was tasked with underperforming retail branch turnarounds where he increased revenue
and profits by more than 300%. In addition, Mr. Torres was an integral member of the customer acquisition teams, whose purpose was to retain and
expand commercial demand accounts and business line of credit growth.
Mr. Torres has spent over 20 years as a chief operating officer in a variety of industries, including consumer durables, heavy equipment, building
products, real estate, and financial services. His understanding and extensive experience of distribution channels encompasses retail sales, wholesale,
catalogue sales, direct sales, leasing, and implementation of Lean manufacturing processes.

In the last five years, Mr. Torres has been responsible for the complete implementation of G FarmaLabs wide vertical integration, encompassing all
aspects from seed to sale and creating processes that capture the spirit of the founders most important philosophy, relentless consistency. This includes
streamlining cannabis production and curing processes, overseeing quality control, and decreasing overall production cost and expenses.

Among his significant previous positions, Mr. Torres served as an Assistant Vice President for Citicorp, in the retail sales division, a New York-based NYSE
and Fortune 500 multinational commercial bank.

Fay Farouk Chief Strategy Officer GFarmaLabs Limited

Seasoned Executive and change management expert with a consistent track record of delivering high value change to Fortune 1000 and multinational
clients. Fay has worked in Executive sector serving as transformation change leader for the last decade. Seasoned in development, design and delivery
of adult management learning and development. Award winning facilitator who has delivered top quality workshops and programs. Fay is an expert of
Peter Drucker's management principals " BusinesWeek Magazine's "father of modern day management"; one of the few people in US that was licensed
by the prestigious "Drucker Institute". Fay has a strong ability to persuade and facilitate change in the midst of difficult obstacles. He's ability to
understand all facets of a business allows him to draw from resources and bring sustainable growth. Fay has delivered over 350 keynotes since 2000.
With over 15+ year track record of success in organizational development, strategy and change management focus with global industry leaders including
Northrop Grumman, Oracle, John Deer, AAA, Adidas, Boeing and many others.

Fay holds a Executive Masters in Business in Executive Management from Claremont Graduate University, Bachelors of Science degree in Business
Management and Consumer Psychology, A lifelong learner, Faiyaz has also received over 10,000 hours of professional public speaking training since
1991. He also holds certificates in Leadership, Management and strategy from Claremont Graduate University.

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

Revenue Stream
G FarmaLabs Actual
Revenue Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15

Inventory 2,400 3,480 7,700 3,540 17,710 24,348 27,032 25,751 14,968 11,206 5,124 4,955 12,336 14,590
G Stiks - 10,080 8,400 6,240 15,456 21,658 20,352 35,112 22,104 25,680 28,608 43,680 55,056 49,402
HOG - 13,600 11,200 8,400 10,280 8,300 6,700 4,500 8,080 6,550 5,550 10,050 8,850 7,900
LG Bars - - 240 21,240 29,106 34,862 25,104 48,337 47,633 74,152 101,040 125,026 108,462 131,816
LG Bars Holiday - - - - - - - 8,398 13,083 23,274 960 - - 120
LG Conf. - - - - - - 570 960 1,374 1,140 1,200 780 495 840
LG Red Vape Oil 28,875 47,050 67,500 55,125 75,100 75,300 62,472 90,762 61,186 70,276 58,934 64,823 48,206 58,949
LG Tanks - - - - - - - - - - - - 36,582 54,065
LG TrufJles 34,920 22,320 29,520 16,200 22,380 19,479 19,476 17,928 18,894 13,920 3,528 19,570 17,599 11,582
others - - 90 - - - - - - - - - - -
NugRun - - - - - - - - - - - - - 32,530
discount - - - - - - - - - - (1,728) (6,224) (15,865) (13,811)
Total Revenue 66,195 96,530 124,650 110,745 170,032 183,947 161,706 231,748 187,322 226,198 203,216 262,660 281,720 347,983
12.6%
Forecast

May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16

16,049 17,654 19,419 21,361 23,497 25,847 28,432 31,275 34,402 37,843 41,627 45,790 50,369 55,406 60,946 67,041 73,745 81,119 89,231 98,154
55,330 61,970 69,406 77,735 87,063 97,511 109,212 122,318 136,996 153,435 171,847 192,469 215,565 241,433 270,405 302,854 339,196 379,900 425,488 476,546
8,690 9,559 10,515 11,566 12,723 13,995 15,395 16,934 18,628 20,491 22,540 24,794 27,273 30,000 33,000 36,300 39,930 43,923 48,316 53,147
147,634 165,350 185,192 207,415 232,305 260,181 291,403 326,372 365,536 409,400 458,529 513,552 575,178 644,200 721,504 808,084 905,054 1,013,661 1,135,300 1,271,536
132 145 160 176 193 213 234 257 283 311 342 377 414 456 501 551 607 667 734 807
924 1,016 1,118 1,230 1,353 1,488 1,637 1,801 1,981 2,179 2,397 2,636 2,900 3,190 3,509 3,860 4,246 4,670 5,137 5,651
64,843 71,328 78,460 86,306 94,937 104,431 114,874 126,361 138,997 152,897 168,187 185,006 203,506 223,857 246,243 270,867 297,953 327,749 360,524 396,576
59,472 65,419 71,961 79,157 87,072 95,779 105,357 115,893 127,482 140,231 154,254 169,679 186,647 205,312 225,843 248,427 273,270 300,597 330,657 363,722
12,740 14,014 15,416 16,957 18,653 20,518 22,570 24,827 27,310 30,041 33,045 36,349 39,984 43,983 48,381 53,219 58,541 64,395 70,834 77,918
- - - - - - - - - - - - - - - - - - - -
35,783 39,361 43,297 47,627 52,390 57,629 63,392 69,731 76,704 84,374 92,812 102,093 112,302 123,533 135,886 149,474 164,422 180,864 198,951 218,846
(15,939) (17,694) (19,644) (21,810) (24,218) (26,893) (29,866) (33,171) (36,844) (40,927) (45,467) (50,514) (56,125) (62,366) (69,305) (77,023) (85,607) (95,156) (105,777) (117,594)
385,658 428,122 475,301 527,720 585,969 650,700 722,640 802,598 891,476 990,275 1,100,112 1,222,231 1,358,014 1,509,002 1,676,912 1,863,654 2,071,356 2,302,389 2,559,393 2,845,310

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

G FarmaLabs
Revenue 2014 (Mar-Dec) 2015 2016 2017 2018 2019
Inventory 138,135 220,540 735,672 1,618,478 1,707,494 1,784,332
G SNks 165,082 857,291 3,306,134 9,091,868 9,819,218 10,408,371
HOG 77,610 131,728 398,342 876,352 937,697 993,959
LG Bars 280,674 2,282,196 8,821,533 23,818,138 25,485,408 26,759,678
LG Bars Holiday 44,755 2,590 6,051 13,312 14,110 14,816
LG Conf. 4,044 13,882 42,355 93,182 98,773 103,711
LG Red Vape Oil 633,645 972,453 2,972,362 6,539,195 6,996,939 7,346,786
LG Tanks - 770,756 2,726,121 5,997,466 6,357,314 6,675,179
LG Trues 215,037 197,974 583,999 1,284,799 1,361,887 1,429,981
others 90 - - - - -
NugRun - 441,740 1,640,261 3,608,574 3,825,088 4,016,343
discount - (226,862) (842,705) (2,101,178.0) (2,246,540.7) (2,362,798.2)
Total Revenue 1,559,072 5,664,287 20,390,124 50,840,186 54,357,387 57,170,358

G Farms 2015 2016 2017 2018 2019

Flower+trim 7,600,000 7,828,000 8,500,000 9,135,000 9,135,000

Total Revenue 13,264,287 28,218,124 59,340,186 63,492,387 66,305,358

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

G FarmaLabs Historical Revenue

400,000

350,000

300,000

250,000

200,000

150,000

100,000

50,000

-
Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15

Inventory G Stiks HOG LG Bars LG Bars Holiday LG Conf. LG Red Vape Oil LG Tanks LG Truffles others NugRun Total Revenue

Figure: G FarmaLabs historical revenue Figure: G FarmaLabs revenue breakdown

We have different product category but so far our most popular product is LG In the first four months of 2015, we managed to achieve
bars. Every product offers a unique market advantage due to their 1.1 million USD and we are on our way to reach the
consistency, design, and the array of compelling choices of flavors and goal of 4.5 million USD by the end of this year. After the
blends. Edibles, confections, Vape Oil, Vape Pens, and G Stiks are few other acquisition and inauguration of Desert hot Spring plant,
product categories that we currently offer. we are expecting to achieve a significant rise in total
revenue from operation starting in 2017. The figure
below shows the forecasted revenue of G FarmaLabs
till 2019.

Desert hot Springs Plant

Figure: G FarmaLabs forecasted revenue

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

EXHIBIT A
Forecasted Revenue calculations

Estimated Loan Amount % of the flower production utilized by the

75%
G FarmaLabs
Land Purchase (2.5 Acres) $330,000.00
% of flower production sold to dispensaries 25%
Conditional Use Permit Fees $75,000.00
Proforma
Miscellaneous fees $10,000.00
Revenue per year G FarmaLabs 75%
Total $415,000.00
3rd
1st scenario 2nd senario
Scenario
Loan repayment Year 1 Year 2 Flower price/lb 1000 2000 3000

Interest rate 10% Trim price/lb 50 100 150

Interest Payment $41,500.00 $41,500.00 Flower 27,000,000 54,000,000 81,000,000

Balloon Payment $415,000.00 Trim 67,500 135,000 202,500

Gross Revenue 27,067,500 54,135,000 81,202,500

Green House Performance

Total Plants 2,400 unit Revenue per year G Farms 25%

Containers 45 Gallon 3rd

1st scenario 2nd senario
Scenario
Product per plant 5 lb
Flower price/lb 500 1000 1500
No of harvests per year 3
Trim price/lb 50 100 150
Total Production 36,000 lbs
Flower 4,500,000 9,000,000 13,500,000
Trim 15%
Trim 67,500 135,000 202,500
Byproduct 5,400 lbs
Gross Revenue 4,567,500 9,135,000 13,702,500

Total Gross revenue 31,635,000 63,270,000 94,905,000

Profit Margin 68% 68% 68%

Total Profit 21,416,895 42,833,790 64,250,685

Valuation 107,084,475 214,168,950 321,253,425

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

EXHIBIT B
Current valuation of the company

Indoor Flowers

Production volume $2,000 lbs/annum

Wholesale price $2,000 $/lb

Gross profit $4,000,000

Profit Margin 50%

Net profit $2,000,000 *50% profit margin

Outdoor flowers

Production volume $3,000 lbs/annum

Wholesale price $1,200 $/lb

Gross profit $3,600,000

Profit Margin 50%

Net profit $1,800,000 *50% profit margin

Valuation for G FarmaLabs

Monthly rrevenue $300,000

Projected annual revenue $4,000,000

Net profit $1,500,000

Total Net profit $5,300,000

Valuation multiple 5 * industry average

Current valuation $26,500,000

www.GFarmaLabs.com
 Financial Performance Desert Hot Springs Project

EXHIBIT C
NPV Calculations

Required Rate of return 10%

Development Cost $5,500,000

Year
0 1 2 3 4 5 6 7 8 9 10
Expense (5,500,000.0) $ (41,500) $ (41,500) 0 0 0 0 0 0 0 0
Return $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580
Cash Flow $ (5,500,000) $ 42,975,080 $ 42,975,080 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580 $ 43,016,580

NPV Production Capacity

$235,223,852 30,000 33,000 36,000 39,000 $42,000 45,000

40% 113,245,370 125,076,454 136,907,539 148,738,624 160,569,708 172,400,793

Margin 50% 142,823,081 157,611,937 172,400,793 187,189,649 201,978,505 216,767,360

60% 172,400,793 190,147,420 207,894,047 225,640,674 243,387,301 261,133,928

68% 195,175,631 215,199,742 235,223,852 255,247,963 275,272,074 295,296,185

70% 201,978,505 222,682,903 243,387,301 264,091,699 284,796,097 305,500,495

75% 216,767,360 238,950,644 261,133,928 283,317,212 305,500,495 327,683,779

www.GFarmaLabs.com
 Industry Overview Desert Hot Springs Project

Governments, entrepreneurs, and people everywhere are beginning to acknowledge that the potential of the cannabis industry is too great
to ignore. Its outdated, unsubstantiated stigma is quickly being replaced by legitimate research, supportive laws, and market demand that
have surpassed expectations.

$3B $30B 23
The current value of the legal marijuana market, The projected value of US retail sales resulting from full States that have already legalized medical marijuana. 11 more
which grew 74% in 2014 legalization have pending legislation in 2015.

76% 17M 52%

of clinicians believe that the medicinal benefits 17 million people already live in states where For the first time in history, a the majority of Americans
outweigh the risks and potential harms recreational marijuana is legal. support marijuana legalization

$500M

The US imports $500M in hemp

Within the next 5 years, the legal
products each year. Now
cannabis industry is expected to Politicians of both parties support
Americans can grow limited
out earn the US film industry, the marijuana law reform
quantities of hemp for the first
organic foods industry
time in 77 years

Figure: Marijuana Industry by numbers

www.GFarmaLabs.com
 Industry Overview Desert Hot Springs Project

The U.S. marijuana industry will pump an estimated $10 billion into state and local economies in 2015, with cannabis sales via dispensaries and
recreational stores accounting for up to $3.1 billion of that total. (Marijuana Business Factbook) It is estimated that for every dollar of cannabis sold at the
retail level in states where medical or recreational cannabis is legal adds at least another $2.60 to the economy, much of it at the local level. This
marijuana multiplier highlights the substantial role the cannabis industry already plays in the U.S. economy and its potential impact going forward. Using
this metric, the industry is expected to generate $30 billion or more annually in economic value by 2019.

*2015 Marijuana business handbook

Revenue generated by dispensaries and retail stores is projected to more than double over
the next few years as more states legalize and the industry expands, hitting $6.5 billion-$8
billion by 2019, according to the Factbook. Sales in 2015 alone are expected to hit $2.7
billion to $3.1 billion, rising 35%-55% from the estimated $2 billion-$2.4 billion dispensaries
and retail stores raked in last year.

The marijuana multiplier is a highly conservative estimate, so the industrys impact could in
reality be much greater than projected.

The $2.60 per $1 in retail marijuana sales takes into account money spent by growers,
retailers, infused product makers, testing labs and ancillary product and services firms on
business expenses, ranging from staff salaries to security. It is based in part on financial
data from over 800 businesses across all sectors of the state-legal marijuana industry

Legal marijuana businesses are valuable to their local economies and, in turn, the national
economy. As more states legalize and the industry goes mainstream, this economic value
will continue to migrate from the black market to the legal markets where it provides
tremendous value for local communities.
Figure: Marijuana sales forecast and impact on the economy*

Looking Forward

2015 Washington states recreational market will finally kick into full gear and generate several hundred million dollars in sales. As of press time, it is also likely that Medical
marijuana Industry will be folded into its recreational cannabis program-which will create some near term turmoil for existing dispensaries but little impact on overall
industry revenue. California might expect some slow down due to local bans and moratoriums as well as dispensary crackdown in Los Angeles. As the California market
is huge, when the state is able to finally get everything in order and regulate as per feds direction, the overall outcome is expected to be spectacular.

Several other state markets are poised for continuing solid growth, including Arizona and New Mexico. In the meantime, Massachusetts, Illinois and Nevada are moving
slowly but steadily. 2016 The newer MMJ states are expected to flourish including but not limited to Minnesota, Oregon and Alaska.

2016-2017 New markets will continue to launch, based on elections and legislative measures that are currently being considered. Current markets will also continue to
evolve and grow as more patients and consumers participate in the legal industry and businesses will drive customers away from the black market.

www.GFarmaLabs.com
 Investment Opportunity Desert Hot Springs Project

Legal marijuana is the fastest-growing industry in the United States and if the trend toward legalization spreads to all 50 states, marijuana could become
larger than the organic food industry. Over the next five years marijuana industry is expected to continue to grow and analysts estimated that 14 more state
will legalize recreational marijuana and two more states will legalize medical marijuana. At least 10 states are already considering legalizing recreational
marijuana in just the next two years through ballot measures or state legislatures.

Medical marijuana and cannabis investments are in high demand among investors. Marijuana
industry consists of different segments like Marijuana Dispensaries, Co-Ops, Cannabis Grow
Rooms, and Websites catering to the marijuana industry, Cannabis Kitchens and anything
else related to Medical Marijuana. Making large profits investing in medical marijuana
businesses can be achieved in a short time, which is the nature of the marijuana business.
The future of MMJ (medical marijuana) investments, investors, banks and retail businesses
brings endless opportunities for private marijuana investors to make great returns on their
investment in businesses like Dispensaries that sell the marijuana, grow-ops which grow the
plants, or the lead/referral generating business which is part of the booming marijuana
technology and internet business.

More than 1.5 million shoppers purchased legal marijuana from a dispensary, either medical
or recreational, in 2014. Five states now boast marijuana markets that are larger than $100
million, and in Colorado and Washington consumers bought $370 million in marijuana
products last year. Oregon and Alaska are expected to add a combined $275 million in retail
marijuana sales in their first year of operation, the report projects.

When the results of new states opening for business along with natural existing market growth
are combined, analyst predict that national sales will at least double and possibly even triple
over the next five years if the current trends continue paying out. The business opportunity
tied to this growth will be immense.

California: the largest state-market in the U.S. at $980 million.

Even without the approval of recreational adult usage in the state. California has a larger market share than the recreationally approved states, including
Colorado and Washington combined. If recreational use is adopted, which we believe to be likely in 2017, the total California market is projected to increase
dramatically and represent an even more dominant share of the national market.

www.GFarmaLabs.com
 Investment Opportunity Desert Hot Springs Project

The legal pot business in the United States, including both the newly legalized retail
operations in Washington and Colorado and the medical-marijuana use now allowed
in California and 22 other states, is expected to grow this year to $2.6 billion from
$1.5 billion in 2013( ArcView Group). In five years, that number could swell to more
than $10 billion. And if backers are successful in getting a legalization measure on
the 2016 ballot in California, the Golden State, with its already outsize medical-pot
market, could soon be entering a Golden Era of commercialized cannabis

Although the state in 1996 became the first in the nation to legalize pot for medicinal
reasons, California has yet to approve it for the overall adult population, or so-called
"adult-use." As marijuana use has become more main stream, a veritable
smorgasbord of professionals and young startups has popped up to feed off and
support the pot culture. There are security outfits protecting Mendocino County
farms and software developers churning out cannabis-news apps and GPS-enabled
tools like Weedly to find the nearest pot club. And there are even pot-friendly resorts
where the Hollywood set can go to get high in peace, provided they have a
prescription.

California's current medical-marijuana industry is riddled with conflicting

laws and policies that can differ city by city, with some pot clubs paying
taxes and others not. Despite the business is booming with no sign of letting
up. An estimated 100,000 Californians already are employed in the industry,
growing pot or servicing suppliers and their customers, a number that would
soar with legalization.

Despite the industry faces years of political and regulatory challenges,

strong revenues and taxes already are collected from medical marijuana.
These are exciting times and new millionaires and possibly billionaires are
about to be made, while simultaneously society will become safer and freer.

Figure: Legalizing marijuana consensus

www.GFarmaLabs.com
 A Picture is Worth a Thousand Words
Cardboard Boxes as Nightstands

GFarmaLabs
2010 Outdoor Season
Plants: 630
Yield: 2,000 lbs.

www.GFarmaLabs.com
 Desert Hot Springs Project
G Farmacy

Click to Watch Video

www.GFarmaLabs.com
 Desert Hot Springs Project
OC Farmacy

Click to Watch Video

www.GFarmaLabs.com
 Desert Hot Springs Project
OC Farmacy High Times

Click to Watch Video

www.GFarmaLabs.com
 Desert Hot Springs Project
Winning a few Trophies helps!

www.GFarmaLabs.com
 Desert Hot Springs Project
Public Speaker and Cannabis Advocate

www.GFarmaLabs.com
 Desert Hot Springs Project
Continued Growth... CA., WA & Beyond...

www.GFarmaLabs.com
 Desert Hot Springs Project
An Idea Becomes Reality

www.GFarmaLabs.com
 Desert Hot Springs Project
An Idea Becomes Reality

www.GFarmaLabs.com
 Desert Hot Springs Project
Our Asian Partners

www.GFarmaLabs.com
 Desert Hot Springs Project
Building Our Latest Facility

www.GFarmaLabs.com
 Desert Hot Springs Project

Welcome Accredited Investors

We welcome working with Accredited Investors to seize tomorrows opportunities today. We look forward to
sharing our Investor Presentation, discussing our operations, and outlining our strategic vision. We enjoy working with
like-minded, forward-thinking investors. If you are an accredited investor looking to invest in the medical marijuana
sector in the United States or abroad, we invite you to contact us to discuss our current and upcoming projects and your
potential level of participation.

Contact
Ata Gonzalez
Director | CEO
ata@GFarmaLabs.com

www.GFarmaLabs.com
 Desert Hot Springs Project

Thank You!
Your investment represents a unique moment in history one that rivals the repeal of prohibition and the power
of an upstart industry. Reports show the United States marijuana market is currently developing faster than the
smartphone and tablet industry, and ushering in a new era of early investors to compliment this revolution. We believe
this happens to be one of the most exciting eras in investing history. This is an age of uprising, of revolution, of new
ideals.

Cultural relevancy is on everybodys minds and lips. Smart investors are doing their homework; and were thankful that
youve taken the time to learn our story and consider us as a part of your portfolio. Early movers in this multibillion dollar
market will surely have an advantage in the exciting marijuana industry. The industry is developing weekly. We see a
great market and future for G FarmaLabs Limited and its shareholders and respectfully request your assistance in
helping us achieve these goals. Its necessary to take risks and its always good business practice to be progressive; but
we advise you to consult with your financial advisor to determine whether an investment in our company is appropriate
for your circumstances and thank you again for the consideration.

www.GFarmaLabs.com
 Desert Hot Springs Project

v e T e a m at Disney,
u ti
Our Exec a t o u r C o re
...
Fa m il y is

Contact Us
Ata Gonzalez | CEO
G FarmaLabs Limited
369 3rd St.
#464
San Rafael CA. 94901
Email: Ata@GFarmaLabs.com
www.GFarmaLabs.com